May 28, 2025

HIV Pill Improves Vision in DME Patients

Lamivudine improved visual acuity in patients with diabetic macular edema, offering a low-cost oral alternative to anti-VEGF eye injections.

Reuters

May 28, 2025

Sleep, Time, Exercise Shift Heart Biomarkers, Study Finds 

Short sleep, late blood draws, and intense workouts significantly change common cardiovascular biomarkers, suggesting key variables often go unaccounted for in heart risk assessments.

Conexiant

May 23, 2025

New Inhaled Treprostinil Option Approved

Yutrepia represents an additional therapeutic option within the prostacyclin class for the management of PAH and PH-ILD.

Conexiant

May 23, 2025

Patients With Psoriasis Show Inflammation Despite Skin Clearance

Over one-third of psoriasis patients had elevated hs-CRP despite biologic treatment and skin clearance, with obesity, female sex, and fatty liver disease identified as key predictors of residual inflammation.

Conexiant

May 23, 2025

BP Pills: Does Timing Matter? 

A large Canadian study of 3,357 patients found that taking blood pressure medication at bedtime did not reduce deaths or heart events compared to morning dosing.

Conexiant

May 23, 2025

Regular Exercise Slows Memory Decline in Seniors

In a study of older adults with memory problems, those who exercised regularly for 12 months had less cognitive decline than those who did not receive any intervention.

Conexiant

May 23, 2025

BMI, Glucose, Blood Pressure Linked to Multimorbidity

A 30-year cohort study found that life-course factors—including BMI, blood pressure, and glucose—significantly influence chronic disease accumulation, but much of the risk remains unexplained.

Conexiant

May 22, 2025

Cardiogenic Shock in Women: Treatment Disparities Persist

New expert consensus statement reveals that women with cardiogenic shock face significant treatment disparities and outlines evidence-based recommendations for improving outcomes.

Conexiant

May 21, 2025

Diabetes Drug TZDs May Curb Prostate Cancer

Older type 2 diabetes drugs that target PPAR-gamma may slow prostate cancer progression.

Reuters